Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis-Reference-Cited by-同舟云学术

Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis

Published:2011-06-30 Issue:10 Volume:52 Page:1936-1941
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Bezares Raimundo Fernando,Stemelin German,Diaz Alicia,Argentieri Daniel,Zubiaur Emilio Lanari,Garay Guy,Bartomioli Miguel,Ryser Ricardo,Milone Gustavo

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.584991

Reference13 articles.

1. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

2. Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

3. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

4. Efficacy and Tolerability of Alemtuzumab (CAMPATH-1H) in the Salvage Treatment of B-Cell Chronic Lymphocytic Leukemia—Change of Regimen Needed?

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant setting;Leukemia & Lymphoma;2024-07

2. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience;American Journal of Hematology;2015-08-14

3. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients;Annals of Hematology;2013-11-30

4. The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy;Expert Review of Anticancer Therapy;2013-09

5. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma;Haematologica;2013-05-03